Free Trial

Spectaire (SPEC) Competitors

Spectaire logo
$0.05 0.00 (0.00%)
(As of 11/12/2024 ET)

SPEC vs. TBIO, THMO, OLITW, PRENW, QSIAW, SMAPW, TT, KEYS, FTV, and VLTO

Should you be buying Spectaire stock or one of its competitors? The main competitors of Spectaire include Telesis Bio (TBIO), ThermoGenesis (THMO), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), Keysight Technologies (KEYS), Fortive (FTV), and Veralto (VLTO). These companies are all part of the "measuring and control equipment" industry.

Spectaire vs.

Telesis Bio (NASDAQ:TBIO) and Spectaire (NASDAQ:SPEC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.

Telesis Bio has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Spectaire has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500.

37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 26.6% of Spectaire shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 25.4% of Spectaire shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Telesis Bio received 9 more outperform votes than Spectaire when rated by MarketBeat users. Likewise, 52.94% of users gave Telesis Bio an outperform vote while only 0.00% of users gave Spectaire an outperform vote.

CompanyUnderperformOutperform
Telesis BioOutperform Votes
9
52.94%
Underperform Votes
8
47.06%
SpectaireOutperform Votes
No Votes
Underperform Votes
1
100.00%

Spectaire has lower revenue, but higher earnings than Telesis Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telesis Bio$27.51M0.07-$47.72M-$28.20-0.04
SpectaireN/AN/A$8.95MN/AN/A

Spectaire has a consensus price target of $2.50, suggesting a potential upside of 4,850.50%. Given Spectaire's stronger consensus rating and higher probable upside, analysts plainly believe Spectaire is more favorable than Telesis Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telesis Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Spectaire
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Spectaire's return on equity of -81.22% beat Telesis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Telesis Bio-336.59% -359.32% -61.89%
Spectaire N/A -81.22%304.57%

In the previous week, Telesis Bio had 1 more articles in the media than Spectaire. MarketBeat recorded 2 mentions for Telesis Bio and 1 mentions for Spectaire. Spectaire's average media sentiment score of 0.00 beat Telesis Bio's score of -0.63 indicating that Spectaire is being referred to more favorably in the news media.

Company Overall Sentiment
Telesis Bio Negative
Spectaire Neutral

Summary

Spectaire beats Telesis Bio on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

MetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ Exchange
Market Cap$930,000.00$19.42B$24.19B$9.02B
Dividend YieldN/A2.91%2.73%4.01%
P/E RatioN/A13.07225.7613.92
Price / SalesN/A11.513,385.1097.63
Price / Cash0.0815.9434.1137.13
Price / Book-0.033.057.136.04
Net Income$8.95M$505.69M$659.35M$225.15M
7 Day PerformanceN/A-0.62%1.13%1.29%
1 Month PerformanceN/A5.64%3.54%6.70%
1 Year PerformanceN/A14.00%23.15%32.94%

Spectaire Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
Spectaire
N/A$0.05
flat
$2.50
+4,850.5%
-97.7%$930,000.00N/A0.008Gap Down
TBIO
Telesis Bio
N/A$1.10
-12.7%
N/A-90.4%$1.95M$27.51M-0.04200Earnings Report
THMO
ThermoGenesis
N/A$0.00
flat
N/A-100.0%$5,000.00$9.44M0.0025
OLITW
OmniLit Acquisition
N/A$0.05
flat
N/A+36.8%$0.00N/A0.003Gap Up
PRENW
Prenetics Global
N/A$0.01
flat
N/A-49.7%$0.00$22.66M0.001Short Interest ↑
QSIAW
Quantum-Si
N/A$0.07
flat
N/A-75.2%$0.00$1.70M0.00159Short Interest ↓
Gap Down
SMAPW
SportsMap Tech Acquisition
N/A$0.05
+71.2%
N/AN/A$0.00N/A0.00N/AGap Up
TT
Trane Technologies
4.1712 of 5 stars
$395.92
+1.0%
N/A+82.4%$89.09B$17.68B36.7340,000Positive News
KEYS
Keysight Technologies
4.3186 of 5 stars
$165.18
+2.1%
N/A+29.8%$28.67B$5.46B31.7714,900Upcoming Earnings
Short Interest ↑
FTV
Fortive
4.8939 of 5 stars
$74.01
-0.4%
N/A+14.0%$25.68B$6.07B29.4918,000Dividend Announcement
Analyst Forecast
Short Interest ↓
VLTO
Veralto
2.6034 of 5 stars
$104.30
+1.3%
N/A+47.1%$25.47B$5.02B32.1916,000Positive News

Related Companies and Tools


This page (NASDAQ:SPEC) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners